Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $29.73, denoting a +0.61% change from the preceding trading day.

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

We recently published a list of 10 Stocks Skyrocketing Today. In this article, we are going to take a look at where Viking ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...

Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...

In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against the other stocks ...